FSD Pharma Inc. Signs Agreement
Ticker: QNTM · Form: 6-K · Filed: Mar 27, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement, filing
TL;DR
FSD Pharma signed a deal, details TBD.
AI Summary
FSD Pharma Inc. filed a Form 6-K on March 27, 2024, to report a press release. The press release, Exhibit 99.1, indicates that FSD Pharma Inc. has signed an agreement. Further details regarding the agreement's nature, parties involved, or financial implications are not provided in this filing.
Why It Matters
This filing signals a new development for FSD Pharma Inc., potentially impacting its business operations or strategic direction, though specifics are not yet disclosed.
Risk Assessment
Risk Level: medium — The filing is a 6-K reporting a signed agreement, but lacks specific details, creating uncertainty about its impact and potential risks.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- March 27, 2024 (date) — Filing Date
FAQ
What is the nature of the agreement signed by FSD Pharma Inc.?
The provided Form 6-K filing does not specify the nature of the agreement signed by FSD Pharma Inc. It is only mentioned in Exhibit 99.1 as a press release announcing the signing.
Who are the parties involved in the agreement?
The filing does not disclose the names of the other parties involved in the agreement signed by FSD Pharma Inc.
What is the financial value or impact of this agreement?
The Form 6-K does not provide any information regarding the financial value or expected impact of the agreement.
When was the agreement officially signed?
While the filing is dated March 27, 2024, and reports on an agreement signed, the exact date of the signing is not explicitly stated within the provided text.
Is this agreement related to FSD Pharma's pharmaceutical preparations business?
The filing does not specify the business segment to which the agreement pertains, although FSD Pharma Inc. is classified under Pharmaceutical Preparations (SIC 2834).
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-03-27 08:01:30
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 15KB
- fsd_ex991img1.gif (GRAPHIC) — 6KB
- 0001654954-24-003684.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: March 27, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3